Drug Trial Radar · NCT00118898
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
Last checked: Nov 20, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,864
Actual
Start
Sep 2005
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jul 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Currently, the preferred anti-HIV regimens used in the United States consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV). However, with new anti-HIV drugs being approved, alternative regimens need to be tested to determine if new drug combinations have increased effectiveness in treating HIV. The purpose of this study is to test the safety, tolerability, and effectiveness of four different regimens in HIV-infected adults who have never taken anti-HIV drugs.
Conditions
- HIV Infections
Interventions
Abacavir/LamivudineDrug
600 mg abacavir/300 mg lamivudine tablet taken orally daily
AtazanavirDrug
300 mg tablet taken orally daily
EfavirenzDrug
600 mg tablet taken orally daily
Emtricitabine/Tenofovir disoproxil fumarateDrug
200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
RitonavirDrug
100 mg tablet taken orally daily
Abacavir/Lamivudine placeboDrug
Placebo tablet taken orally daily
Emtricitabine/Tenofovir disoproxil fumarate placeboDrug
Placebo tablet taken orally daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to Virologic FailureTime frame: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
- Time From Treatment Dispensation to a Grade 3/4 Safety EventTime frame: All follow-up while on initially assigned regimen; the median (25th, 75th percentile) follow-up while on initial regimen was 120 (54, 156) weeks and the range was 0 to 205 weeks.
- Time From Treatment Dispensation to Treatment ModificationTime frame: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
Usc Crs (1201)
Los Angeles, California
UCLA CARE Center CRS (601)
Los Angeles, California
Stanford CRS (501)
Palo Alto, California
Ucsd, Avrc Crs (701)
San Diego, California
Ucsf Aids Crs (801)
San Francisco, California
San Mateo County AIDS Program (505)
Stanford, California
Willow Clinic (507)
Stanford, California
Harbor-UCLA Med. Ctr. CRS (603)
Torrance, California
University of Colorado Hospital CRS (6101)
Aurora, Colorado
Georgetown University CRS (GU CRS) (1008)
Washington D.C., District of Columbia
University of Miami AIDS CRS (901)
Miami, Florida
Emory University
Atlanta, Georgia
The Ponce de Leon Center CRS (5802)
Atlanta, Georgia
Northwestern University CRS (2701)
Chicago, Illinois
Cook County Hospital Core Center (2705)
Chicago, Illinois
Rush Univ. Med. Ctr. ACTG CRS (2702)
Chicago, Illinois
Indiana University Hospital (2601)
Indianapolis, Indiana
Wishard Hospital (2603)
Indianapolis, Indiana
Univ of Iowa Hosp and Clinic (1504)
Iowa City, Iowa
IHV Baltimore Treatment CRS (4651)
Baltimore, Maryland
Johns Hopkins Adult AIDS CRS (201)
Baltimore, Maryland
Massachusetts General Hospital ACTG CRS (101)
Boston, Massachusetts
Brigham and Women's Hosp. ACTG CRS (107)
Boston, Massachusetts
Bmc Actg Crs (104)
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
Boston, Massachusetts
Washington U CRS (2101)
St Louis, Missouri
SUNY - Buffalo (Rochester) (1102)
Buffalo, New York
Cornell CRS (7804)
New York, New York
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)
New York, New York
NY Univ. HIV/AIDS CRS (401)
New York, New York
HIV Prevention & Treatment CRS (30329)
New York, New York
Harlem ACTG CRS (31483)
New York, New York
AIDS Community Health Ctr. ACTG CRS (1108)
Rochester, New York
University of Rochester ACTG CRS (1101)
Rochester, New York
Unc Aids Crs (3201)
Chapel Hill, North Carolina
Wake County Department of Health (30076)
Chapel Hill, North Carolina
Duke University Medical Center Adult CRS (1601)
Durham, North Carolina
Moses H. Cone Memorial Hospital CRS (3203)
Greensboro, North Carolina
University of Cincinnati CRS (2401)
Cincinnati, Ohio
Case CRS (2501)
Cleveland, Ohio
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.